Highly Efficient Lentiviral Gene Transfer in CD34 + and CD34 + /38 − /lin − Cells from Mobilized Peripheral Blood after Cytokine Prestimulation
- 1 July 2003
- journal article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 21 (4) , 472-480
- https://doi.org/10.1634/stemcells.21-4-472
Abstract
Because mobilized peripheral blood (mPB) represents an attractive source of cells for gene therapy, we investigated lentiviral gene transfer in CD34(+) cells and the stem/progenitor-cell-enriched CD34(+)/38(-)/lin(-) cell subset isolated from mPB. In this study, we used an optimized third-generation self-inactivating lentiviral vector containing both the central polypurine tract and the woodchuck hepatitis posttranscriptional regulatory element sequences and encoding enhanced green fluorescent protein (EGFP) under the control of the elongation factor lalpha promoter. This lentivector was first used to compare multiplicity of infection (MOI)-dependent gene transfer efficiency in cord blood (CB) versus mPB CD34(+)-derived cells, colony-forming cells (CFCs), and long-term culture-initiating cells (LTC-ICs). Results showed a difference in the percentage of transduced cells particularly significant at low MOIs. A plateau was reached where 15% and 25% of CB and mPB cells, respectively, remained refractory to lentiviral trans-duction. Effects of a cytokine prestimulation period (18 hours) with interleukin-3, stem cell factor, Flt-3 ligand, and thrombopoietin were then analyzed in total cells, CFCs, and LTC-ICs derived from mPB CD34(+) cells. Transduction levels in those conditions demonstrated a two- and fourfold increase in CFCs and LTC-ICs, respectively, compared with unstimulated (85% of colonies derived from LTC-ICs expressing EGFP and gene transfer levels remaining stable for 10 weeks in liquid culture. We therefore demonstrate a highly efficient gene transfer in this therapeutically relevant target cell population.Keywords
This publication has 39 references indexed in Scilit:
- Risks and Benefits of Gene Therapy for Immunodeficiency: a Reality CheckGene Therapy, 2002
- Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesisBlood, 2002
- Efficient Oncoretroviral Transduction of Extended Long-Term Culture-Initiating Cells and NOD/SCID Repopulating Cells: Enhanced Reconstitution with Gene-Marked Cells Through anEx VivoExpansion ApproachHuman Gene Therapy, 2002
- Transient detection of β-galactosidase activity in hematopoietic cells, following reinjection of retrovirally marked autologous blood progenitors in patients with breast or ovarian cancer receiving high-dose chemotherapyExperimental Hematology, 2002
- Enhanced Transgene Expression in Cord Blood CD34+-Derived Hematopoietic Cells, Including Developing T Cells and NOD/SCID Mouse Repopulating Cells, Following Transduction with Modified TRIP Lentiviral VectorsMolecular Therapy, 2001
- Efficient Human Immunodeficiency Virus-Based Vector Transduction of Unstimulated Human Mobilized Peripheral Blood CD34+Cells in the SCID-hu Thy/Liv Model of Human T Cell LymphopoiesisHuman Gene Therapy, 2001
- Lentiviral Vectors for Enhanced Gene Expression in Human Hematopoietic CellsMolecular Therapy, 2000
- Human Cord Blood CD34+CD38- Cell Transduction via Lentivirus-Based Gene Transfer VectorsHuman Gene Therapy, 1999
- In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral VectorScience, 1996
- Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors.Journal of Clinical Investigation, 1994